degrader antibody conjugates

Roche takes ‘leap of faith’ with bet on C4T’s protein degraders

Roche has joined its peers in the degrader-antibody conjugate space, paying C4T more than $1 billion in milestones to partner on two oncology targets.

Nick Paul Taylor Apr 9, 2026 7:00am

Nurix gets BTK degrader back on track after FDA lifts hold

Mar 11, 2024 9:25am

Are DACs the new ADCs? Seagen pays Nurix $60M to find out

Sep 7, 2023 10:35am